The value of tirofiban in non-macrovascular occlusive ischemic stroke beyond time window

doi:10.3969/j.issn.1672-6731.2020.08.015

Abstract

Abstract:

Objective To observe the clinical value of early application of tirofiban in patients with non-macrovascular occlusive ischemic stroke beyond time window. Methods Clinical data of 90 patients with non-macrovascular occlusive ischemic stroke treated beyond time window from April 2017 to April 2019 were retrospectively analyzed. According to different treatment, they were divided into 2 groups, one group given tirofiban combined with double antibody treatment (treatment group, 50 cases) and another group given double antibody treatment only (control group, 40 cases). National Institutes of Health Stroke Scale (NIHSS) was used to evaluate the neurological status of patients on the 1st, 3rd and 7th day of treatment. On the day of admission and 3 months after treatment, modified Rankin Scale (mRS) and Activities of Daily Living Scale (ADL) were used to evaluate the neurological recovery and activities of daily living. The occurrence of bleeding and severe thrombocytopenia (platelet count < 100×10⁹/L) during the treatment was also recorded in 2 groups. Results Differences in NIHSS scores between 2 groups at different time points after treatment were statistically significant (P=0.000). On the 7th day of treatment in the control group, the NIHSS scores were lower than those on the 1st day (P=0.000) and on the 3rd day (P=0.000), which suggested that the degree of neurological deficits had improved. The NIHSS scores on the 1st, 3rd and 7th day after treatment showed a gradual downward trend (P=0.000, for all), and was significantly lower than the control group (P=0.000). After 3 months of treatment in 2 groups, the mRS score was lower than that before treatment (P=0.000), while the ADL score was higher than that before treatment (P=0.000). The mRS score in the treatment group was lower than control group (P=0.000), and the ADL score was higher than control group (P=0.003). There was no significant difference in the incidence of bleeding and severe thrombocytopenia between the treatment group and the control group[26% (13/50) vs. 35% (14/40); χ²=0.483, P=0.439]. Conclusions The early application of tirofiban in patients with non-macrovascular occlusive ischemic stroke beyond time window can significantly improve the patient's neurological function, improve the quality of life and activities of daily living.

Key words: Stroke, Brain ischemia, Platelet aggregation inhibitors

摘要：

目的探讨超时间窗非大血管闭塞性缺血性卒中患者早期应用替罗非班的临床价值。方法对2017年4月至2019年4月的90例超时间窗非大血管闭塞性缺血性卒中患者临床资料进行回顾分析，根据不同治疗方案分为替罗非班联合双联抗血小板治疗组（治疗组，50例）和单纯双联抗血小板治疗组（对照组，40例）；于治疗第1、3和7天进行神经功能缺损程度[美国国立卫生研究院卒中量表（NIHSS）]评价，入院当日与治疗3个月后进行神经功能恢复[改良Rankin量表（mRS）]和日常生活活动能力[日常生活活动能力量表（ADL）]评价，并记录两组患者治疗期间出血及严重血小板减少事件（血小板计数< 100×10⁹/L）的发生情况。结果治疗后不同时间点两组NIHSS评分差异具有统计学意义（P=0.000）。对照组治疗第7天时，NIHSS评分低于第1天（P=0.000）和第3天（P=0.000）；治疗组治疗后第1、3和7天NIHSS评分呈逐渐下降趋势（均P=0.000），且明显低于对照组（P=0.000）。两组治疗3个月后，mRS评分（P=0.000）低于、ADL评分高于（P=0.000）治疗前，且治疗组mRS评分低于（P=0.000）、ADL评分高于（P=0.003）对照组。治疗组与对照组患者出血及严重血小板减少事件发生率差异无统计学意义[26%（13/50）对35%（14/40）；χ²=0.483，P=0.439]。结论对于超时间窗非大血管闭塞性缺血性卒中患者，发病早期静脉应用替罗非班能够显著改善其神经功能，提高生活质量和日常生活活动能力。

关键词: 卒中, 脑缺血, 血小板聚集抑制剂

ZHOU Xing-chen, SHU Han-sheng, WANG Da-wei, ZHANG Hui, WANG Hao, YANG Guang, MIN Jing-liang. The value of tirofiban in non-macrovascular occlusive ischemic stroke beyond time window[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(8): 740-745.

周星辰, 束汉生, 王大巍, 张辉, 王昊, 杨光, 闵敬亮. 替罗非班在超时间窗非大血管闭塞性缺血性卒中中的应用价值[J]. 中国现代神经疾病杂志, 2020, 20(8): 740-745.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2020.08.015

https://journal11.magtechjournal.com/cjcnn/EN/Y2020/V20/I8/740

References

[1] GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18:459-480.
[2] Yang XY, Hao JJ, Li G. Research progress on risk factors for ischemic stroke[J]. Zhonghua Wei Sheng Ying Ji Dian Zi Za Zhi, 2019, 5:57-60.[杨心怡, 郝俊杰, 李刚. 缺血性脑卒中危险因素研究进展[J]. 中华卫生应急电子杂志, 2019, 5:57-60.]
[3] Chinese Society of Neurology, Chinese Medical Association; Neurovascular Intervention Group, Chinese Society of Neurology, Chinese Medical Association. Chinese guidelines for the endovascular treatment of acute ischemic stroke 2018[J]. Zhonghua Shen Jing Ke Za Zhi, 2018, 51:683-691.[中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组, 中华医学会神经病学分会神经血管介入协作组. 中国急性缺血性脑卒中早期血管内介入诊疗指南2018[J]. 中华神经科杂志, 2018, 51:683-691.]
[4] Chinese Society of Neurology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Zhonghua Shen Jing Ke Za Zhi, 2018, 51:666-682.[中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51:666-682.]
[5] Geng T, Song ZY, Wang BX, Xu ZS. Safety and effectiveness of combination application of thrombus aspiration and intracoronary injection of tirofiban[J]. Chongqing Yi Xue, 2018, 47:211-213.[耿涛, 宋志远, 王炳勋, 徐泽升. 联合应用血栓抽吸及冠状动脉内注射替罗非班的安全性和有效性[J]. 重庆医学, 2018, 47:211-213.]
[6] Zhao ZL, Shi JY, Ren XA, Tu XT, Wei W, Fu XL. Clinical value of tirofiban in patients with acute myocardial infarction before emergency intervention[J]. Lin Chuang Jun Yi Za Zhi, 2018, 46:1203-1204.[赵志林, 史静怡, 任旭爱, 涂晓彤, 魏维, 伏晓琳. 急性心肌梗死患者急诊介入术前应用替罗非班临床价值研究[J]. 临床军医杂志, 2018, 46:1203-1204.]
[7] Wang YH, Shi YJ, Xu W, Li JX, Niu LL. Study of low-dose tirofiban in the treatment of acute ST-segment elevation myocardial infarction in elderly women underwent primary PCI[J]. Zhongguo Xun Zheng Xin Xue Guan Yi Xue Za Zhi, 2018, 10:615-617.[王玉红, 石宇杰, 徐威, 李俊峡, 牛丽丽. 低剂量替罗非班对老年女性急性ST段抬高型心肌梗死患者急诊PCI治疗疗效[J]. 中国循证心血管医学杂志, 2018, 10:615-617.]
[8] Liu W, Wang ZR, Guo QD, Zhang XW, Zhang L, Fu LA, Fei Z. Treatment of acute thrombosis in stent-assisted embolization of intracranial aneurysms[J]. Zhonghua Shen Jing Wai Ke Ji Bing Yan Jiu Za Zhi, 2018, 17:130-134.[刘伟, 王卓然, 郭庆东, 张鑫伟, 张磊, 付洛安, 费舟. 颅内动脉瘤支架辅助栓塞术中急性血栓形成的治疗[J]. 中华神经外科疾病研究杂志, 2018, 17:130-134.]
[9] Lin L. Safety and efficacy of tirofiban in acute ischemic stroke patients[D]. Chongqing:Third Military Medical University, 2017.[林露. 替罗非班治疗急性缺血性卒中的安全性与有效性研究[D]. 重庆:第三军医大学, 2017.]
[10] Ji L, Jiang Y, Yue CX, Ye D, Liu M, Wu J, Sheng SY, Lian XG. Evaluation value of extended NIHSS on medullary infarction with NIHSS score=0[J]. Lin Chuang Shen Jing Bing Xue Za Zhi, 2018, 31:418-421.[季蕾, 蒋颖, 岳春贤, 叶丹, 刘猛, 吴坚, 盛世英, 练学淦. 扩展版NIHSS对NIHSS评分0分延髓梗死的评估价值[J]. 临床神经病学杂志, 2018, 31:418-421.]
[11] Fan YH, Ji XT, Lan LF. The application of mRS in the methods of outcome assessment in Chinese stroke trials[J]. Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi, 2015, 41:412-415.[范玉华, 姬晓昙, 蓝琳芳. 国内脑卒中临床试验疗效判断方法中改良Rankin评分的应用现状[J]. 中国神经精神疾病杂志, 2015, 41:412-415.]
[12] Deng RY, Xing FM, Wang L, Zhao HY. Influence of ADL system intervention on movement function and quality of life of stroke patients[J]. Jilin Da Xue Xue Bao (Yi Xue Ban), 2011, 37:1129-1132.[邓荣悦, 邢凤梅, 王莉, 赵焕英. 日常生活能力系统干预对脑卒中患者的运动功能及生活质量的影响[J]. 吉林大学学报(医学版), 2011, 37:1129-1132.]
[13] Chen RH, Cao J, Xuan JG, Zhu XC, Shao MH, Peng Y. Outcomes and influencing factors of endovascular treatment in acute ischemic stroke with large vessels occlusion of cerebral anterior circulation[J]. Zhonghua Shen Jing Yi Xue Za Zhi, 2018, 17:784-789.[陈荣华, 曹洁, 宣井岗, 朱旭成, 邵华明, 彭亚. 急性前循环大血管闭塞血管内治疗效果及影响因素分析[J]. 中华神经医学杂志, 2018, 17:784-789.]
[14] Wang M, Zhou JS, Wu AY. Research progress in intravenous thrombolysis and endovascular treatment of acute ischemic stroke[J]. Zhonghua Shen Jing Ke Za Zhi, 2017, 50:391-395.[王蒙, 周俊山, 吴奥燕. 急性缺血性卒中静脉溶栓及血管内治疗研究进展[J]. 中华神经科杂志, 2017, 50:391-395.]
[15] Xiao TG, He DT, Chen JM, Huang K, Li N, Chen F, Wang B. Emphasis on metabolic syndrome to prevent stroke[J]. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, 2014, (8):1007-1009.[肖铁刚, 何道同, 陈珺明, 黄侃, 李娜, 陈放, 王兵. 重视代谢综合征有效预防脑卒中[J]. 中西医结合心脑血管病杂志, 2014, (8):1007-1009.]
[16] Xiang W, Deng Z. Research progress of endothelial microRNAs and ischemic stroke[J]. Yi Xue Zong Shu, 2017, 23:1888-1893.[项薇, 邓镇. 内皮微RNA与缺血性脑卒中的研究进展[J]. 医学综述, 2017, 23:1888-1893.]
[17] Huang S, Zhou F, Zhang YD. Research progress of tirofiban in acute ischemic stroke[J]. Zhongguo Nao Xue Guan Bing Za Zhi, 2018, 15:601-606.[黄石, 周峰, 张颖冬. 替罗非班在急性缺血性卒中中的研究进展[J]. 中国脑血管病杂志, 2018, 15:601-606.]
[18] Li W, Lin L, Zhang M, Wu Y, Liu C, Li X, Huang S, Liang C, Wang Y, Chen J, Feng W. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke, 2016, 47:2649-2651.
[19] He MF, Wang TT, Gao F, Tian SC, Ma XZ, Cui HQ, Dong G. Therapeutic effect of tirofiban on progressive ischemic stroke[J]. Zhongguo Shi Yong Shen Jing Ji Bing Za Zhi, 2018, 21:2249-2253.[何明峰, 王婷婷, 高飞, 田松朝, 马兴洲, 崔会青, 董歌. 替罗非班治疗进展性缺血性脑卒中的疗效观察[J]. 中国实用神经疾病杂志, 2018, 21:2249-2253.]
[20] Shi PX. Effect of local administration of tirofiban via arterial catheter on regional blood flow and neurological function in patients with acute ischemic cerebral infarction with thrombolysis time window exceeding[J]. Zhongguo Shi Yong Yi Kan, 2019, 46:104-106.[史鹏新. 替罗非班经动脉导管局部给药对溶栓时间窗超出的急性缺血性缺血性卒中患者局部血流及神经功能的影响[J]. 中国实用医刊, 2019, 46:104-106.]

Please choose a citation manager

Content to export